Financials data is unavailable for this security.
View more
Year on year ACADIA Pharmaceuticals Inc grew revenues 40.45% from 517.24m to 726.44m while net income improved from a loss of 215.98m to a smaller loss of 61.29m.
Gross margin | 91.61% |
---|---|
Net profit margin | 13.83% |
Operating margin | 12.08% |
Return on assets | 15.97% |
---|---|
Return on equity | 27.36% |
Return on investment | 24.34% |
More ▼
Cash flow in USDView more
In 2023, ACADIA Pharmaceuticals Inc increased its cash reserves by 61.20%, or 73.81m. Cash Flow from Investing totalled 32.00m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company generated 16.70m in cash from operations while cash generated from financing totalled 25.13m.
Cash flow per share | 0.8485 |
---|---|
Price/Cash flow per share | 21.19 |
Book value per share | 3.47 |
---|---|
Tangible book value per share | 2.84 |
More ▼
Balance sheet in USDView more
Current ratio | 2.29 |
---|---|
Quick ratio | 2.11 |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼